Dr. Audra L. Clos, MD

Dr. Clos practices at Bayou City Dermatology - HOPD in Webster, Texas.

Dr. Clos' NPI, 1952601122, was assigned on October 22, 2010. Dr. Clos graduated from UTMB Health in 2010. Dr. Clos' Texas license number on file is P0361.

Dr. Clos' primary practice is Bayou City Dermatology - HOPD, at 202 N Texas Ave, Webster, TX 77598.

Dr. Clos' primary practice is Bayou City Dermatology - HOPD in Webster, Texas. The medical group on file is Bayou City Dermatology. Dmand AI also links Dr. Clos to 1 more group practice or clinic, named with a free account. Dr. Clos' employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Clos practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Clos' primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Clos is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Clos' licenses on file in 2 states: Texas and Indiana.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, itchy rashes and psoriasis among the conditions Dr. Clos treats.

CMS data shows 4,476 Medicare services from Dr. Clos across 20 procedure codes in 2024, for 524 Medicare patients. Medicare paid $209,249 for them. Every service was in an office.

CMS counts 524 Medicare patients who saw Dr. Clos in 2024. The largest group is 65 to 74, with 308 patients. 75% of them have high cholesterol, and 72% have high blood pressure. Their average risk score is 1.04, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Clos' median patient age at 65, with 60% women.

In 2024, Dr. Clos wrote 1,739 Medicare Part D claims for 503 patients. 94% of them were for generic drugs. CMS names the drug for 1,620 of them, across 33 drugs with 11 or more claims each, at $298,810 in total drug cost. In 2023, CMS named 1,279 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Clos for performance year 2024, reported as part of a group. Dr. Clos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 1,049 procedures of skin biopsy by Dr. Clos, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 14 papers to Dr. Clos, published from 2010 to 2015. 2010 was the busiest year, with 4. The most frequent topics are Skin Neoplasms. Dr. Clos has published most often in Biochem Biophys Res Commun. Dr. Clos' most frequent co-authors are Brent Christopher Kelly, MD, George Robert Jackson, MD and Richard F. Wagner, MD.

CMS Open Payments shows 1,159 general payments to Dr. Clos from 46 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 71% of the total. Allergan Inc. paid the most, $4,662.

Dr. Clos graduated from UTMB Health in 2010. Dr. Clos is a member of AAD, Texas Dermatologic Society and TMA.

Dr. Clos is in network with 21 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.